UK Pharma Exports Gain US Tariff Exemption as Trump Administration Reshapes Trade Landscape with Targeted Agreements

Listeners, welcome back to United Kingdom Tariff News and Tracker, where we break down how today’s trade moves are reshaping the UK economy and its ties with Washington. The big story is the evolving tariff landscape between the United States under President Trump and the United Kingdom, with medicines and industrial goods at the center of the action. According to the Tax Policy Center, the Trump administration has rolled out a sweeping 10 percent minimum tariff on all imported goods, alongside higher “reciprocal” tariffs for around 60 countries. In that broad package, an important carve‑out was negotiated for the UK. The White House announced an agreement with the United Kingdom to exempt UK cars, steel, and aluminum from that 10 percent blanket tariff rate, sparing key British exports from a direct hit at the US border. But that exemption comes against a tougher global backdrop. The same Tax Policy Center tracking shows that 25 percent tariffs on steel and aluminum were reinstated generally, with earlier exemptions for partners including the European Union and the United Kingdom removed in other contexts, signaling that any UK advantage is highly specific and could be revisited as broader tariff policy shifts. The most closely watched development for listeners in the UK right now is in pharmaceuticals. Grant Thornton reports that on December 1 the US and UK announced an agreement in principle to exempt UK‑origin prescription drugs, pharmaceutical ingredients, and medical technology from pending US tariffs tied to a Section 232 national security investigation. Under the framework described by the US Trade Representative, the UK’s National Health Service will increase the net price it pays for medicines to 25 percent and cut the rebate rate it recovers from drug companies to 15 percent in 2026, effectively trading higher domestic prices for continued zero‑tariff access into the US market. This pharma angle is reinforced by updates to the UK‑US Prosperity Deal. Legal analysts at Mondaq note that the deal includes a zero percent tariff on UK pharmaceutical exports to the US for three years, a move designed to protect UK‑based manufacturing and support long‑term investment in high‑value life sciences. Nasdaq commentary adds that this landmark zero‑tariff arrangement is already being priced into markets, with expectations that major US and UK pharma players, and the ETFs that track them, will gain from more predictable, tariff‑free trade in medicines and medical technology. All of this is unfolding as US imports overall soften and markets wait on a Supreme Court ruling that could redefine presidential authority over tariffs, according to shipping analysts at Lloyd’s List. For the United Kingdom, that means today’s exemptions and zero‑tariff deals are valuable, but not guaranteed, and listeners should expect tariff policy to remain a moving target throughout the Trump term. Thanks for tuning in to United Kingdom Tariff News and Tracker. Be sure This content was created in partnership and with the help of Artificial Intelligence AI.